What the FDA labels say about taking them together
Desipramine and dextroamphetamine
Dextroamphetamine's FDA label of November 26, 2025 names desipramine in its drug interactions section; the desipramine labels PlainMeds reads (2) do not name dextroamphetamine. The dextroamphetamine label: “Tricyclic Antidepressants Clinical Impact May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of dextroamphetamine in the brain; …”
Check it at the source: the desipramine FDA label on DailyMed (effective July 9, 2025, Alembic Pharmaceuticals Inc.); the dextroamphetamine FDA label on DailyMed (effective November 26, 2025, Azurity Pharmaceuticals, Inc.).
What does the desipramine label say about dextroamphetamine?
Desipramine's label (effective July 9, 2025) and its 1 other brand-application label do not name dextroamphetamine in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (DESIPRAMINE HYDROCHLORIDE), Alembic Pharmaceuticals Inc., effective July 9, 2025 (SPL set cad14805-64d8-4257-b5f1-d56e0063f0e2), via openFDA; the full label on DailyMed
What does the dextroamphetamine label say about desipramine?
Dextroamphetamine label, drug interactionsAntidepressants, Tricyclic Amphetamines may enhance the activity of tricyclic or sympathomimetic agents; d -amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d -amphetamine in the brain; cardiovascular effects can be potentiated.
Xelstrym label (Noven Therapeutics, LLC, December 23, 2025), drug interactions… when XELSTRYM is co-administered [see CLINICAL PHARMACOLOGY (12.3) ]. From a pharmacokinetic perspective, no dose adjustment for drugs that are substrates of CYP1A2 (e.g. theophylline, duloxetine, melatonin), CYP2D6 (e.g. atomoxetine, desipramine, venlafaxine), CYP2C19 (e.g. omeprazole, lansoprazole, clobazam), and CYP3A4 (e.g. midazolam, pimozide, simvastatin) is necessary when XELSTRYM is co-administered [see CLINICAL PHARMACOLOGY (12.3) ].
Source: FDA drug label (Xelstrym, NDA215401), Noven Therapeutics, LLC, effective December 23, 2025 (SPL set 0862f02a-72a8-41cc-8845-57cf4974bb6f), via openFDA
Source: FDA drug label (Zenzedi), Azurity Pharmaceuticals, Inc., effective November 26, 2025 (SPL set d6394df5-f2c9-47eb-b57e-f3e9cfd94f84), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Desipramine | Dextroamphetamine | |
|---|---|---|
| Labeled for | Depression | ADHD |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.276 per tablet 75 mg tablet | $0.373 per tablet 10 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once